1574P - Medical oncology residents mentors (MORM): A target for resiliency interventions

Background

The MORM plays a pivotal role in the teaching and learning process for residents, which is crucial for the quality of training received by medical oncology (MO) specialists. However, there is a lack of regulatory framework regarding the system of specialized healthcare training, and anecdotally, there is a lack of definition of time-specific dedication to carry out these responsibilities during the workday, which may lead to resignation and burnout. The objective of this study is to identify, describe and analyze the profile of MORM, assess their capacity for resilience and compare them with a general group of MO. The results of this study will serve as the basis for developing potential resiliency interventions on MORM that may enhance their commitment to the role and prevent burnout.

Methods

Two anonymous online surveys on resilience were conducted among SEOM MO members in 2023. One survey was a general resilience survey sent to MO and the second one was focused on MORM. The results of the questionnaires were compared to identify differential features in both cohorts that could inform about resilience-related actions.

Results

304/3397 (9%) MO and 114/224 (51%) MORM completed the surveys. 95% of the whole population had >5 years-experience, 34% had only an assistant profile and 44% had an assistant profile combined with research activity. An 80% of them spent time working outside work hours and about 50% practiced sports or hobbies ≥ 2 times per week (20% only on weekends and 33% never). More than 80% do not eat properly and sleep less than 7 h/day. Only 34% had a restful sleep during the week. Of note, 61.4% feel undervalued in their mentor’s role. Moreover, 46% of MORM felt anxious due to workload vs 23% of MO, and 73% of MORM arrived on holidays mentally exhausted vs 33% of MO. Despite this, 30% of MORM admit suffering from burnout vs 43% of MO. Interestingly, 77% of MORM believe they have the resources to improve their resilience on themselves vs 62% of MO.

Conclusions

Interventions to help MORMs may be considered to improve work and life balance such as optimizing time spent outside work hours, improving healthy diet or sleeping habits. The management of the organizations must consider these interventions a priority.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

D. Paez: Financial Interests, Personal, Invited Speaker: MSD, Novartis, BMS; Financial Interests, Personal, Advisory Board: Amgen, Esteve, Ipsen; Financial Interests, Personal and Institutional, Research Grant: Merck. M.E. Elez Fernandez: Financial Interests, Personal, Advisory Board: Hoffman La - Roche, Servier, Amgen, Merck Serono, Sanofi, Bayer, Pierre Fabre, MSD, Takeda, Boehringer Ingelheim, Cure Teq AG, Repare Therapeutics Inc., RIN Institute Inc., Janssen; Financial Interests, Personal, Invited Speaker: Organon, Novartis, Pfizer, BMS, Lilly, Medscape; Financial Interests, Personal, Other, Educational training: Seagen International GmbH; Financial Interests, Institutional, Funding: Hoffmann-La Roche Ltd, Sanofi Aventis Recherche & Développement, Amgen Inc., Boehringer Ingelheim, Novartis Farmacéutica SA, Bristol Myers Squibb International Corporation, BeiGene, HalioDX SAS, Janssen-Cilag SA, Merck Health KGAA, Merck Sharp & Dohme de España SA, PharmaMar SA, Servier, Taiho Pharma USA Inc, Hutchison MediPharma International, Menarini, Merus NV, Pfizer, Mirati, Array Biopharma Inc, AstraZeneca Pharmaceuticals LP, Celgene International SARL, Debiopharm International SA, Genentech Inc, MedImmune, AbbVie Deutschland Gmbh & Co KG, Bayer Pharma AG, Bioncotech Therapeutics, S.L., Biontech Rna Pharmacuticals GMBH, Biontech Small Molecules GMBH, Boehringer Ingelheim de España S.A., Daiichi Sankyo, Inc, Gercor, Hutchinson Medipharma Limited, Iovance Biotherapeutics, Inc., Janssen Research & Development, Menarini Ricerche SPA, Merck, Sharp & Dohme De España S.A., Nouscom SRL., Pledpharma AB, Redx Pharma PLC, Scandion Oncology, Seattle Genetics Inc., Sotio A.S., Wntresearch AB; Non-Financial Interests, Other, Coordinator of the SEOM +MIR Section of Residents and Young Assistants: Sociedad Española de Oncología Médica (SEOM); Non-Financial Interests, Other, Speaker of the ESMO Academy: European Society for Medical Oncology (ESMO); Non-Financial Interests, Other, Volunteer member of the ASCO Annual Meeting Scientific Program Committee: Developmental Therapeutics – Immunotherapy: American Society of Clinical Oncology (ASCO); Non-Financial Interests, Leadership Role, Member of the Scientific Program Committee and Developmental Therapeutics-Immunotherapy Track Leader, 2023-2024 term: American Society for Clinical Oncology (ASCO); Non-Financial Interests, Other, Member of the Scientific Committee 2024: European Society for Medical Oncology (ESMO); Other, Travel, accommodations, expenses.: Roche, Merck Serono, Sanofi, Amgen, Array BioPharma, Servier, Bristol Myers Squibb. All other authors have declared no conflicts of interest.